Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel

NEWARK, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
December 04, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel

NEWARK, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 13, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Three Investor Conferences

NEWARK, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 08, 2017 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates

NEWARK, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 01, 2017 08:30 ET | Source: CymaBay Therapeutics, Inc.

CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8

NEWARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
October 31, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer

NEWARK, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
October 23, 2017 16:30 ET | Source: CymaBay Therapeutics, Inc.

CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis

NEWARK, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
October 09, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting

- Interim phase 2 study results demonstrate the potential for superior efficacy and better tolerability over existing second-line therapy - CymaBay will also present new clinical research on...
September 18, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Two Investor Conferences

NEWARK, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
September 11, 2017 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis

NEWARK, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...